Decentralized Clinical Trial Oversight: The COVID-19 Effect
Improve Decentralized Trial Execution and Operational Efficiencies with RBQM The COVID-19 pandemic has placed greater importance on risk management, and has re...
Executive Abstract
The COVID-19 pandemic has placed greater importance on risk management, and has required clinical trial sites, sponsors, and clinical research organizations (CROs) to adopt remote and risk-based quality management (RBQM) methodologies for clinical trial execution to:
Many have recognized great improvements in trial execution and operational efficiencies with this adoption, while others are struggling with how to implement an RBQM approach.
Read this white paper to learn the current state of RBQM approaches to providing decentralized clinical oversight, and the value that adopting these approaches brings to sponsors, CROs, sites, and ultimately patients.
Unlock Report Access
Complete this brief form for instant PDF access.
Related Executive Research
White Paper
How To Choose An Immunoassay Platform For Cell & Gene Therapy Bioanalysis
The key factors to automating assay development to get results quicker Given the recent approval of an adeno-associated viral (AAV) vector gene therapy for spi...
Guide
Chronic Obstructive Pulmonary Disease- Pipeline Analysis 2018
There are total 141 molecules in pipeline (Company Molecules 90, University & Institute Molecules 51) in different phases of development. There are total 141 m...
White Paper
Increasing Patient Engagement and Helping Clinical Trials Reach Full Potential with the Clinical Research as a Care Option Model
Only 3% of people with cancer participate in clinical trials. CRAACO seamlessly integrates clinical research with medical care, so more patients and physicians...